Waregem

Epstein-Barr Virus EBV infects most adults worldwide and can cause various diseases including infectious mononucleosis and chronic fatigue syndrome. This trial evaluates two drugs, 2LEBV and 2LXFS, to study their effects on reducing fatigue and other symptoms related to EBV infection. The study aims to provide new information on their effectiveness compared to placebo in treating EBV infections. Participants will take one capsule daily of either 2LEBV, 2LXFS, or placebo for six continuous months. Capsules are taken sequentially by number, one per day before breakfast on an empty stomach. The treatment follows a specific order from capsule 1 through 10, repeated continuously for the full treatment duration. During the study, participants will complete fatigue questionnaires called the Multidimensional Fatigue Inventory-20 MFI-20 to measure general and specific types of fatigue. Researchers will also monitor other EBV symptoms, lymphocyte typing, and safety by tracking adverse events over six to twelve months. Participation involves regular assessments through the treatment period and beyond to evaluate the drugs impact on fatigue and symptoms.

Researchers are collecting detailed data about suicide attempts and suicidal thoughts among people who come to healthcare services in Flanders. The study aims to understand how often these behaviors occur, the methods used, and how many receive proper follow-up care after a suicide attempt. This observational study uses a structured interview tool called the Guideline for Suicide Care and Evaluation LOES to gather comprehensive information. Participants undergo a two-part semi-structured interview administered by trained nurses, psychologists, or psychiatrists. The first part happens soon after admission to a healthcare facility and collects information on emotional state, mental health history, social support, hopelessness, and suicidal behavior. The second part provides a deeper evaluation of risk factors, treatment needs, motivations, planning, and coping strategies related to suicidality. Throughout the study, participants provide demographic, clinical, and psychological information through interviews. Researchers assess suicidal intent, planning, past behavior, substance use risk, and care needs. The study tracks treatment agreements and care pathways after assessment. Data collection occurs at the initial presentation, with no drug or medical treatment being tested. The total participation time varies depending on the individuals healthcare encounters and follow-up.